rebel Financial rebel Financial
← All Posts
DRL

Dr. Reddy's Laboratories Limited

July 24, 2026 • Author: Phil Ratcliff • DRL
Item Proposal Vote
1 To receive, consider and adopt the Audited Financial Statements (Standalone and Consolidated) of the Company for the financial year ended March 31, 2026, together with the Reports of the Board of Directors and Auditors thereon. ✓ For
2 To declare a final dividend of Rs. 8/- per equity share of the face value of Rs. 1 each, for the financial year ended March 31, 2026. ✓ For
3 To re-appoint Mr. K Satish Reddy (DIN: 00129701), as a Director, who retires by rotation, and being eligible, offered himself for re-appointment. ✗ Against
4 To appoint M/s. Deloitte Haskins & Sells, LLP, Chartered Accountants as Statutory Auditors for a period of five consecutive years and fix their remuneration. ✓ For
5 To re-appoint Dr. K P Krishnan (DIN: 01099097), as an Independent Director for a second term of five consecutive years. ✓ For
6 To appoint Mr. Srikanth Velamakanni (DIN: 01722758), as an Independent Director for a term of five consecutive years. ✓ For
7 To ratify remuneration payable to cost auditors, M/s. Sagar & Associates, Cost Accountants, for the Financial Year ending March 31, 2027. ✓ For
Attachments
📄
RDY_PROXY_STATEMENT.pdf 0.7 MB
This article was written for information purposes only and its content should not be construed by any consumer and/or prospective client as rebel Financial's solicitation to affect, or attempt to affect transactions in securities, or the rendering of personalized investment advice for compensation. No client or prospective client should assume that any such discussion serves as the receipt of, or a substitute for, personalized advice from rebel Financial, or from any other investment professional. See our disclosures page for more information.